A genetic variant in pseudogene E2F3P1 contributes to prognosis of hepatocellular carcinoma

Journal of Biomedical Research

Volumn 28, Issue 3, 2014, Pages 194-200

  Pan, Yun ^a   Sun, Chongqi ^a   Huang, Mingde ^a   Liu, Yao ^b   Qi, Fuzhen ^a   Liu, Li ^c   Wen, Juan ^a   Liu, Jibin ^d   Xie, Kaipeng ^a   Ma, Hongxia ^a   Hu, Zhibin ^a   Shen, Hongbing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d NANTONG TUMOR HOSPITAL   (China)

Author keywords

E2F3P1; Hepatocellular carcinoma (HCC); Prognosis; Pseudogene; SNP

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; E2F3P1 GENE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSEUDOGENE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84923844487     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.28.20140052     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61: 69-90.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7:237-57.
4. Liang KH, Lin CC, Yeh CT. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. Pharmacogenomics 2011;12:1061-73.
5. LIovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000;31:1019-21.
6. Han YJ, Ma SF, Yourek G, Park YD, Garcia JG. A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J 2011;25:2305-12.
7. Hawkins PG, Morris KV. Transcriptional regulation of Oct4 by a long non-coding RNA antisense to Oct4-pseudogene 5. Transcription 2010;1:165-75.
8. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010;465:1033-8.
9. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011;146:353-8.
10. Poliseno L. Pseudogenes: newly discovered players in human cancer. Sci Signal 2012;5:re5.
11. Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, Robinson DR, Wu YM, Cao X, et al. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell 2012;149:1622-34.
12. Tam OH, Aravin AA, Stein P, Girard A, Murchison EP, Cheloufi S, et al. Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature 2008;453:534-8.
13. Zhou BS, Beidler DR, Cheng YC. Identification of antisense RNA transcripts from a human DNA topoisomerase I pseudogene. Cancer Res 1992;52:4280-5.
14. Kandouz M, Bier A, Carystinos GD, Alaoui-Jamali MA, Batist G. Connexin43 pseudogene is expressed in tumor cells and inhibits growth. Oncogene 2004;23:4763-70.
15. Ishiguro T, Sato A, Ohata H, Sakai H, Nakagama H, Okamoto K. Differential expression of nanog1 and nanogp8 in colon cancer cells. Biochem Biophys Res Commun 2012;418:199-204.
16. Kastler S, Honold L, Luedeke M, Kuefer R, Möller P, Hoegel J, et al. POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. Prostate 2010;70:666-74.
17. Poliseno L, Haimovic A, Christos PJ, Vega Y Saenz de Miera EC, Shapiro R, Pavlick A, et al. Deletion of PTENP1 pseudogene in human melanoma. J Invest Dermatol 2011;131:2497-500.
18. Zhang J, Wang X, Chen B, Xiao Z, Li W, Lu Y, et al. The human pluripotency gene NANOG/NANOGP8 is expressed in gastric cancer and associated with tumor development. Oncol Lett 2010;1:457-63.
19. Diskin SJ, Capasso M, Schnepp RW, Cole KA, Attiyeh EF, Hou C, et al. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet 2012;44:1126-30.
20. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010;10:389-402.
21. Hu L, Zhai X, Liu J, Chu M, Pan S, Jiang J, et al. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology 2012;55:1426-31.
22. Xie K, Liu J, Zhu L, Liu Y, Pan Y, Juan Wen, et al. A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. Cancer Epidemiol 2013;37:998-1002.
23. Gomez-Rodrguez R, Romero-Gutierrez M, Artaza-Varasa T, Gonzá lez-Frutos C, Ciampi-Dopazo JJ, de-la-Cruz-Perez G, et al. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. Rev Esp Enferm Dig 2012;104: 298-304.
24. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
25. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992;258:424-9.
26. Wong JV, Dong P, Nevins JR, Mathey-Prevot B, You L. Network calisthenics: control of E2F dynamics in cell cycle entry. Cell Cycle 2011;10:3086-94.
27. Kong LJ, Chang JT, Bild AH, Nevins JR. Compensation and specificity of function within the E2F family. Oncogene 2007;26:321-7.
28. Li W, Ni GX, Zhang P, Zhang ZX, Li W, Wu Q. Characterization of E2F3a function in HepG2 liver cancer cells. J Cell Biochem 2010;111:1244-51.
29. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 2011;128:1758-69.
30. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004;23:5871-9.
31. Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, et al. E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Cancer Res 2010;70:4613-23.
32. Shi Z, Derow CK, Zhang B. Co-expression module analysis reveals biological processes, genomic gain, and regulatory mechanisms associated with breast cancer progression. BMC Syst Biol 2010;4:74.
33. Echols N, Harrison P, Balasubramanian S, Luscombe NM, Bertone P, Zhang Z, et al. Comprehensive analysis of amino acid and nucleotide composition in eukaryotic genomes, comparing genes and pseudogenes. Nucleic Acids Res 2002;30:2515-23.
34. Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, et al. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 1993;13:7813-25.
35. Han ZB, Zhong L, Teng MJ, Fan JW, Tang HM, Wu JY, et al. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 2012;6:445-57.
36. Tu HF, Liu CJ, Chang CL, Wang PW, Kao SY, Yang CC, et al. The association between genetic polymorphism and the processing efficiency of miR-149 affects the prognosis of patients with head and neck squamous cell carcinoma. PLoS One 2012;7:e51606.
37. Wang F, Ma YL, Zhang P, Shen TY, Shi CZ, Yang YZ, et al. SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol 2013;229:12-24.
38. Li D, Chen P, Li XY, Zhang LY, Xiong W, Zhou M, et al. Grade-specific expression profiles of miRNAs/mRNAs and docking study in human grade I-III astrocytomas. OMICS 2011;15:673-82.